Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Pharma is betting big on connecting potential patients to its medications. It's just the beginning
Last year
Pharma
Marketing
Zymeworks removes CFO; Gilead extends Nurix deal
Last year
News Briefing
Acorda files for bankruptcy, agrees to sell MS drug and other assets to Merz for $185M
Last year
Deals
Pharma
Ipsen boards ADC train in $900M pact with Sutro
Last year
Deals
Pharma
Gritstone's Phase 2 cancer vaccine trial misses the mark, stock spirals down
Last year
R&D
Lonza taps Siegfried leader Wolfgang Wienand as new CEO
Last year
People
Manufacturing
Three more I-Mab execs exit after US/China operations split
Last year
People
China
Verve pauses lead base editing program after safety event, switches focus to follow-up candidate near clinic
Last year
R&D
Cell/Gene Tx
Roivant announces study win in eye disease for Pfizer asset, plans $1.5B share buyback
Last year
Deals
R&D
Providence spinout Praia Health raises $20M
Last year
Startups
Health Tech
Congress' China hawks seek to add biotech suppliers to Pentagon warning list
Last year
China
FDA+
CBER's Marks points to stockpiles of H5N1 vaccine as officials monitor reported human case
Last year
Pharma
FDA+
EU's pharma legislative reforms 'will scare investment away,' Astellas executive says
Last year
Pharma
Law
Gilead partners for ballroom dancing workshop on sexual health and HIV prevention
Last year
Pharma
Marketing
Eiger files for bankruptcy and will wind down operations after years of setbacks
Last year
People
Pharma
BMS' confirmatory trial of Krazati hits primary endpoint following 2022 accelerated approval
Last year
Pharma
FDA+
Liquidia wins against United Therapeutics in patent battle over PAH drug
Last year
Pharma
Law
Omega cuts 35% of workforce; Rhythm, CervoMed, Surrozen raise new funding
Last year
News Briefing
Carisma to lay off staff, drop clinical CAR-M program in favor of second candidate
Last year
People
R&D
Disc Medicine blames 'outsized' placebo response on mixed Phase 2 data in rare blood disorder
Last year
R&D
FDA delays decision on Applied Therapeutics’ rare metabolic disease drug
Last year
FDA+
FDA asks Biogen and Eisai to provide more data on subcutaneous Leqembi
Last year
Pharma
FDA+
Q&A: Insitro CEO Daphne Koller on ‘potentially destructive’ AI hype, Nvidia's chips, and biotech's data problem
Last year
People
R&D
Contineum says it will seek $136M in IPO to back its mid-stage neuro drug
Last year
Financing
Startups
First page
Previous page
187
188
189
190
191
192
193
Next page
Last page